Based on molecular status, the OS improvement was confirmed for EGFR wild-type lung cancers (OS hazard ratio (HR): 0.67; p < 0.001], but not in those EGFR mutated (OS HR: 1.11; p = 0.54), although no clear conclusions can be drawn due to the limited number of patients as part of subgroup analyses. The gene discussed is EGFR; the disease is lung carcinoma.